ArticleInternational journal of clinical pharmacy2026
Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn's disease: a propensity score-adjusted real-world study.
Shangzhan Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.